Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheim
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.
Story
JPost.com - Business & Innovation · Israel
Join the conversation
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.